Fox Run Management L.L.C. Makes New $1.30 Million Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Fox Run Management L.L.C. bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 35,900 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,298,000. Fox Run Management L.L.C. owned about 0.07% of Supernus Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Exchange Traded Concepts LLC grew its holdings in Supernus Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after purchasing an additional 560 shares during the period. HighTower Advisors LLC lifted its position in shares of Supernus Pharmaceuticals by 7.3% during the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock valued at $330,000 after buying an additional 624 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Supernus Pharmaceuticals by 0.5% during the 4th quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company’s stock worth $6,236,000 after acquiring an additional 800 shares during the period. Swiss National Bank grew its stake in shares of Supernus Pharmaceuticals by 0.7% during the 4th quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company’s stock worth $3,920,000 after acquiring an additional 800 shares during the period. Finally, Quartz Partners LLC raised its stake in Supernus Pharmaceuticals by 3.0% in the 4th quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company’s stock valued at $1,031,000 after acquiring an additional 820 shares during the period.

Supernus Pharmaceuticals Trading Down 0.5 %

Shares of SUPN opened at $32.15 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market cap of $1.79 billion, a PE ratio of 30.05 and a beta of 0.83. The stock has a 50-day moving average price of $35.68 and a 200-day moving average price of $35.07.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 over the last three months. 9.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 16th. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.